Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All

It's possible that potential risk for thromboembolic events flagged in rheumatoid arthritis studies could be managed in labeling.

Rheumatoid-Arthritis-Hands_1200

Analysts expect that the resubmission of Eli Lilly & Co./Incyte Corp.'s JAK1/2 inhibitor baricitinib in rheumatoid arthritis will be successful and that the drug will be received warmly in the market by specialists, despite concerns by the US FDA about thromboembolic safety.

Lilly and Incyte announced Aug. 30 that they will be resubmitting the NDA for the once-daily JAK inhibitor in moderate-to-severe...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category